Huntington National Bank Prothena Corp Public LTD CO Transaction History

Huntington National Bank

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$24.75 - $40.66 $2,945 - $4,838	119 Added 150.63%	198 $4,000
Q4 2023 Feb 07, 2024	BUY	$32.31 - $52.32 $2,423 - $3,924	75 Added 1875.0%	79 $2,000
Q1 2023 May 10, 2023	SELL	$46.97 - $58.27 $3,240 - $4,020	-69 Reduced 94.52%	4 $0
Q3 2017 Oct 24, 2017	BUY	$53.83 - $67.75 $3,929 - $4,945	73	73 $5,000

186

42.8M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $646M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

Stay updated on Huntington National Bank with notifications on news.